Top 5 news happening in the AI space:

• Potential US Ban on AI Chip Exports to China Stirs Tech Market

• Google DeepMind Targets OpenAI's ChatGPT with New Gemini Chatbot

• OpenAI Introduces Bing-Enabled Web Search Feature on ChatGPT

• Microsoft's AI-Powered Shopping Features Come to Bing and Edge

• AI-Developed Drug to Begin Human Trials in Revolutionary Healthcare Move

Potential US Ban on AI Chip Exports to China Stirs Tech Market

New export restrictions on AI chips to China are being deliberated by the US, causing Nvidia and AMD shares to dip. Pending commerce department decisions could halt chip shipments as early as July, further complicating the tech trade.

Google DeepMind Targets OpenAI's ChatGPT with New Gemini Chatbot

Google DeepMind is set to launch Gemini, a chatbot expected to rival OpenAI's ChatGPT. Combining the strengths of AlphaGo-type systems with advanced language capabilities, Gemini is anticipated to provide breakthroughs in the AI chatbot sector. With the generative AI market expected to reach $109.37 billion by 2030, the race for dominance is intensifying.

OpenAI Introduces Bing-Enabled Web Search Feature on ChatGPT

OpenAI has announced a new web search feature for its ChatGPT Plus chatbot, powered exclusively by Bing. Available on iOS and Android, this browsing feature supports queries on current events and information beyond the bot's original training data. However, the Bing-only search capability, a result of OpenAI's partnership with Microsoft, has raised concerns due to past criticisms of Bing's search results.

Microsoft's AI-Powered Shopping Features Come to Bing and Edge

Microsoft is enriching its Bing search engine and Bing AI chatbot in Edge with several AI-assisted shopping tools. The capabilities include automatic generation of buying guides, review summaries, and a Price Match feature to request matched prices from retailers. While some see the potential for disrupting existing buying guide sites, Microsoft's innovations aim to provide more utility to its users.

AI-Developed Drug to Begin Human Trials in Revolutionary Healthcare Move

Insilico Medicine's artificial intelligence-developed pharmaceutical drug is set to be tested on 60 people for treating chronic lung disease. This marks a significant step in AI's involvement in drug development as the industry has long faced challenges in bringing new medicines to market.

Between 2000 and 2015, 86% of new drugs failed to meet their goals, showing a clear need for more efficient development processes. AI seems to be a promising solution, as showcased by Insilico's success, enabling drugs to be ready for trials within months.

Cool finds around the web

• This AI Beats Humans at Predicting Song Hits.

• ChatGPT.js - enables easy, efficient interaction with ChatGPT in JavaScript.

• Hyperline - Find the right pricing model for your startup.

• MotionGPT - generates high-quality motions and text descriptions seamlessly.

• MobileSAM - a powerful, user-friendly AI tool to quickly segments anything.

• Need to raise money for your idea quickly? Use this!

^{Thanks for tuning into today's edition!}

^{For Daily AI Content 👇}